Literature DB >> 9807563

Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US.

C Bartolozzi1, R Lencioni, P Ricci, A Paolicchi, P Rossi, R Passariello.   

Abstract

PURPOSE: To investigate the ability of contrast agent-enhanced color Doppler ultrasonography (US) in evaluating the response of hepatocellular carcinoma (HCC) to percutaneous ethanol injection (PEI).
MATERIALS AND METHODS: Forty-two patients (36 men, six women; age range, 51-79 years) with 54 1.3-7.0-cm-diameter (mean +/- SD, 2.8 cm +/- 1.1) HCC lesions were examined with contrast-enhanced color Doppler US before and after PEI. Spiral computed tomography (CT) and percutaneous biopsy also were performed to establish the outcome of therapy.
RESULTS: Before PEI, intratumoral color signals were demonstrated at contrast-enhanced color Doppler US in 47 (87%) lesions (in 40 patients). After PEI, blood flow signals were no longer detected in all 34 of the lesions that were found to be necrotic at spiral CT and biopsy. In 12 (92%) of 13 lesions containing residual viable tumor, intratumoral color signals corresponding to the enhancing areas at spiral CT were still identified at contrast-enhanced color Doppler US. These 12 lesions were retreated with PEI by targeting the areas of residual tumor with contrast-enhanced color Doppler US guidance. Complete necrosis was seen after the second PEI cycle in nine of 12 lesions.
CONCLUSION: Contrast-enhanced color Doppler US shows promise in assessing the therapeutic effect of PEI on HCC and in guiding additional treatment in cases of incomplete response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9807563     DOI: 10.1148/radiology.209.2.9807563

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute.

Authors:  Yoichi Okada; Hiroyasu Ina; Kazunori Kubota; Yoshiro Himeno; Toshihiko Wakita; Isamu Ohashi; Naoya Gomi; Tetsuo Yoshida; Sunao Mae; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

Review 2.  Recent applications of ultrasound: diagnosis and treatment of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaaki Ebara
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

3.  Qualitative diagnosis of hepatocellular carcinoma by contrast enhanced ultrasonography using Coded Harmonic Angio with Levovist.

Authors:  Toshiko Hirai; Hajime Ohishi; Etsuko Tokuno; Miho Takahashi; Hiroshi Sakaguchi; Hiroshi Anai; Yuko Nishimoto; Shinji Hirohashi; Kimihiko Kichikawa
Journal:  J Med Ultrason (2001)       Date:  2002-03       Impact factor: 1.314

4.  Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

Authors:  Guan-Tarn Huang; Po-Huang Lee; Yuk-Ming Tsang; Ming-Yang Lai; Pei-Ming Yang; Rey-Heng Hu; Pei-Jer Chen; Jia-Horng Kao; Jin-Chuan Sheu; Cha-Ze Lee; Ding-Shinn Chen
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

5.  Assessment of hepatic VX2 tumors of rabbits with second harmonic imaging under high and low acoustic pressures.

Authors:  Wen-Hua Du; Wei-Xiao Yang; Xiang Wang; Xiu-Qin Xiong; Yi Zhou; Tao Li
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 6.  Current role of ultrasound for the management of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

Authors:  R Vilana; L Bianchi; M Varela; C Nicolau; M Sánchez; C Ayuso; M García; M Sala; J M Llovet; J Bruix; C Bru
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 7.034

8.  Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Pei-Li Fan; Yu-Quan Xiong; Peng-Yuan Zhuang; Wei Zhang; Hua-Xiang Xu; Dong-Mei Gao; Ling-Qun Kong; Lu Wang; Wei-Zhong Wu; Zhao-You Tang; Hong Ding; Hui-Chuan Sun
Journal:  BMC Cancer       Date:  2011-01-20       Impact factor: 4.430

9.  Endovascular treatment of primary hepatic tumours.

Authors:  Bogdan Popa; Monica Popiel; Laurenţiu Gulie; Claudiu Turculeţ; Mircea Beuran
Journal:  J Med Life       Date:  2008 Oct-Dec

10.  Hepatocellular carcinoma - issues in imaging.

Authors:  C H Thng; Y T Kuo
Journal:  Cancer Imaging       Date:  2004-10-20       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.